Loading...
Market
Story
Johnson & Johnson's Rybrevant Approved for EGFR-Mutated NSCLC, Reduces Progression Risk by 50%
Sep 20, 2024, 09:56 AM
Rybrevant (amivantamab-vmjw), developed by Johnson & Johnson, has received FDA approval in the U.S. for the treatment of second-line EGFR-mutated advanced lung cancer (NSCLC). This approval marks the third new indication for Johnson & Johnson in 2024. Rybrevant, in combination with standard of care, is the first and only targeted regimen to reduce the risk of disease progression by more than 50% in patients with EGFR ex19del/L858R substitution mutations after progression on or after EGFR TKI (MARIPOSA-2). Johnson & Johnson aims to achieve $5 billion in sales for Rybrevant.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $1 billion • 25%
$1 billion - $1.5 billion • 25%
$1.5 billion - $2 billion • 25%
More than $2 billion • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
Less than 10 • 25%
10-20 • 25%
21-30 • 25%
More than 30 • 25%
Lung cancer related indication • 25%
Other cancer indication • 25%
Non-cancer indication • 25%
No new approval • 25%